big pharma hasn’t taken a bite yet so there must be some decent risks in ph3 result - dropping $500M is nothing for big pharma vs potential sales of few $B per year
Ann: Opthea Completes Enrollment in Phase 3 Clinical Program, page-19
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $735.5M | |||
| Open | High | Low | Value | Volume |
| 59.0¢ | 60.3¢ | 58.5¢ | $374.2K | 626.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 72322 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.5¢ | 65222 | 25 |
View Market Depth
| Last trade - 12.22pm 12/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |